Oral GLP-1 vs Injection Pens: What's the Difference, Which to Choose

Oral GLP-1 pills and injection pens belong to the same drug class and work on the same principle. The key differences are frequency (a daily pill vs a weekly injection), use conditions, and — most decisive for patients in Thailand right now — registration status: as of August 2026, based on public Thai FDA records, every GLP-1 registered for weight management in Thailand is an injectable.

What forms does GLP-1 come in?

GLP-1 receptor agonists split into two broad forms by how they’re taken:

1. Subcutaneous injection pens — the widely used group today, e.g. Mounjaro (tirzepatide, a dual GIP + GLP-1 agonist), Wegovy and Ozempic (semaglutide), and Saxenda (liraglutide). Most are injected once weekly; liraglutide is daily.
2. Oral tablets — currently two main types: oral semaglutide (Rybelsus), a peptide in pill form, and orforglipron (Foundayo), the first small-molecule (non-peptide) oral GLP-1 approved in the US (April 2026) for long-term weight management.

Both forms mimic the GLP-1 hormone released after eating: you feel full sooner, appetite drops, and stomach emptying slows — helping many people eat less. Individual response varies.

Which forms are actually usable in Thailand today?

A point worth separating clearly: what “exists in the world” and what is “actually usable in Thailand” are not the same thing. The status as of August 2026, from public records:

Registered indications differ per drug — some are registered for weight management, others primarily for type 2 diabetes. The summary: the GLP-1 pill available in Thailand today (Rybelsus) is not registered specifically for weight management, and the GLP-1 options doctors currently use for weight management are injection pens. Which drug applies to you is a medical decision based on your indication.

Pill vs pen — where exactly do they differ?

The overlooked factor is consistency: a pill sounds easier, but it must be taken correctly every single day, while a pen only needs remembering once a week. For some people the weekly injection is actually easier to sustain than a daily tablet — your own habits matter as much as the drug.

Is one more effective than the other?

Each drug’s trial figures were measured in different populations and conditions, so they can’t be pitted against each other directly. What current data supports: the new pills produce weight loss in the same direction as injectable GLP-1s — e.g. orforglipron’s phase-3 ATTAIN-1 trial reported an average of about 12% weight loss over 72 weeks at the study’s top dose, while each injectable has its own figures from its own trials.

More important than trial averages: individual results spread widely, depending on the dose reached, dietary change, and your body’s response. Trial numbers are a directional guide, not a promise — individual outcomes are never certain.

Do side effects differ?

The symptoms fall in the same class-wide group, because these are the same drug class — but frequency and severity differ per drug according to each one’s trial data. The common effects of both pills and pens are gastrointestinal: nausea, constipation, diarrhea and vomiting, mostly early on or when stepping the dose up, and usually easing as the body adjusts. Starting low and titrating gradually under a doctor’s care reduces the chance of these.

Precautions and contraindications follow each drug’s label — common examples include pregnancy or planned pregnancy, a history of pancreatitis, or a family history of certain thyroid cancers. A doctor always takes your history and assesses before starting.

Which should you choose — the factors doctors weigh

The most useful answer is: “the one that fits your circumstances and is actually usable for your indication.” Doctors typically weigh:

• Indication and Thai availability — is the goal weight management or diabetes care, and is that form registered for the matching indication?
• Daily habits — are you better with daily discipline (pill) or weekly (injection)?
• Feelings about needles — highly needle-anxious patients may suit a pill once one is registered for the matching indication; meanwhile, current pens use very fine needles and doctors teach self-injection until you’re comfortable.
• Health conditions and current medicines — the main determinant of which drug is possible at all.
• Follow-up — every option requires periodic medical follow-up for both results and side effects.

At Onnyx Clinic, the physician runs a doctor-supervised weight-management program using Thai-FDA-registered medicines, with a health assessment before every case, injection training, and ongoing follow-up. If you’re interested — or undecided while waiting for the pill — consult the doctor via LINE @onnyxclinic or 092-789-0742. Results vary by individual.

References

• Rybelsus (oral semaglutide) drug registration — Thai FDA National Drug Information database
• FDA approves Foundayo (orforglipron) — Eli Lilly press release
• Eli Lilly — ATTAIN-1 results (orforglipron)
• Oral GLP-1 receptor agonists in obesity management — PMC
• Thai Food and Drug Administration (FDA)
• Thai FDA National Drug Information database — for checking any drug’s registration status